Bicara Therapeutics (BCAX) Shares Outstanding (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Shares Outstanding data on file, last reported at $65.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 20.21% year-over-year to $65.5 million; the trailing twelve-month figure through Mar 2026 stood at $65.5 million (up 20.21% YoY), and the FY2025 full-year result was $56.6 million, up 3.97% from the prior year.
• Shares Outstanding for Q1 2026 stood at $65.5 million, up from $56.6 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $65.5 million in Q1 2026 and bottomed at $579975.0 in Q3 2023.
• The 4-year median for Shares Outstanding is $54.4 million (2024), against an average of $36.1 million.
• The widest annual swing landed in 2024, when Shares Outstanding jumped 9281.39%; it then increased 0.37% in 2025.
• A 4-year view of Shares Outstanding shows it stood at $640386.0 in 2023, then jumped by 8401.12% to $54.4 million in 2024, then grew by 3.97% to $56.6 million in 2025, then gained by 15.81% to $65.5 million in 2026.
• The last three Shares Outstanding figures came in at $65.5 million (Q1 2026), $56.6 million (Q4 2025), and $54.6 million (Q3 2025), per Business Quant data.

Peer Comparison